ZA200409481B - Combination therapy and means for carrying out said therapy - Google Patents
Combination therapy and means for carrying out said therapy Download PDFInfo
- Publication number
- ZA200409481B ZA200409481B ZA200409481A ZA200409481A ZA200409481B ZA 200409481 B ZA200409481 B ZA 200409481B ZA 200409481 A ZA200409481 A ZA 200409481A ZA 200409481 A ZA200409481 A ZA 200409481A ZA 200409481 B ZA200409481 B ZA 200409481B
- Authority
- ZA
- South Africa
- Prior art keywords
- active compound
- time
- administration
- tts
- long period
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 238000002648 combination therapy Methods 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000000443 aerosol Substances 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 229940035676 analgesics Drugs 0.000 claims description 7
- 239000000730 antalgic agent Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 239000000939 antiparkinson agent Substances 0.000 claims 2
- 229940125688 antiparkinson agent Drugs 0.000 claims 2
- 230000001813 broncholytic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000007921 spray Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 208000000003 Breakthrough pain Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- -1 levorpharnol Chemical compound 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical group C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical class O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940051805 benzomorphan derivative analgesics Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 229960002710 levomethadone Drugs 0.000 description 1
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229940051807 opiod analgesics morphinan derivative Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10230558A DE10230558B4 (de) | 2002-07-05 | 2002-07-05 | Medizinisches Set zur Verabreichung in einer Kombinationstherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200409481B true ZA200409481B (en) | 2006-07-26 |
Family
ID=29761717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200409481A ZA200409481B (en) | 2002-07-05 | 2004-11-24 | Combination therapy and means for carrying out said therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060062735A1 (pt) |
| EP (1) | EP1519712A1 (pt) |
| JP (1) | JP2005535645A (pt) |
| CN (1) | CN1665481A (pt) |
| AU (1) | AU2003281248A1 (pt) |
| BR (1) | BR0312333A (pt) |
| CA (1) | CA2488556A1 (pt) |
| DE (1) | DE10230558B4 (pt) |
| IL (1) | IL166025A0 (pt) |
| MX (1) | MXPA05000293A (pt) |
| PL (1) | PL374509A1 (pt) |
| RU (1) | RU2005102820A (pt) |
| WO (1) | WO2004004681A1 (pt) |
| ZA (1) | ZA200409481B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005007859A1 (de) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| EP0681490A4 (en) * | 1993-01-29 | 1996-03-20 | Miris Medical Corp | METHOD OF TREATING RESPIRATORY DISEASES. |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| SE9601527D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally alministered acetylcysteine as mucolytic agent |
-
2002
- 2002-07-05 DE DE10230558A patent/DE10230558B4/de not_active Expired - Fee Related
-
2003
- 2003-06-12 BR BR0312333-2A patent/BR0312333A/pt not_active IP Right Cessation
- 2003-06-12 AU AU2003281248A patent/AU2003281248A1/en not_active Abandoned
- 2003-06-12 WO PCT/EP2003/006146 patent/WO2004004681A1/de active Application Filing
- 2003-06-12 JP JP2004518524A patent/JP2005535645A/ja not_active Abandoned
- 2003-06-12 EP EP03740228A patent/EP1519712A1/de not_active Withdrawn
- 2003-06-12 PL PL03374509A patent/PL374509A1/xx not_active Application Discontinuation
- 2003-06-12 CA CA002488556A patent/CA2488556A1/en not_active Abandoned
- 2003-06-12 RU RU2005102820/14A patent/RU2005102820A/ru not_active Application Discontinuation
- 2003-06-12 MX MXPA05000293A patent/MXPA05000293A/es unknown
- 2003-06-12 US US10/520,152 patent/US20060062735A1/en not_active Abandoned
- 2003-06-12 CN CN03815425.0A patent/CN1665481A/zh active Pending
-
2004
- 2004-11-24 ZA ZA200409481A patent/ZA200409481B/en unknown
- 2004-12-02 IL IL16602504A patent/IL166025A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2488556A1 (en) | 2004-01-15 |
| MXPA05000293A (es) | 2005-03-31 |
| US20060062735A1 (en) | 2006-03-23 |
| EP1519712A1 (de) | 2005-04-06 |
| PL374509A1 (en) | 2005-10-31 |
| IL166025A0 (en) | 2006-01-15 |
| RU2005102820A (ru) | 2005-08-20 |
| DE10230558B4 (de) | 2007-08-02 |
| BR0312333A (pt) | 2005-04-12 |
| AU2003281248A1 (en) | 2004-01-23 |
| CN1665481A (zh) | 2005-09-07 |
| WO2004004681A1 (de) | 2004-01-15 |
| DE10230558A1 (de) | 2004-01-22 |
| JP2005535645A (ja) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bakshi et al. | Iontophoretic skin delivery systems: Success and failures | |
| AU2005224182B2 (en) | Means for transdermal administration of nicotine | |
| WO2006031856A2 (en) | Biosynchronous transdermal drug delivery | |
| JP2013516482A (ja) | 局所経皮用デクスメデトミジン組成物およびそれらの使用方法 | |
| CA2598406C (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| Stanley | Anesthesia for the 21st century | |
| JPH04128231A (ja) | ブプレノルフインを経皮的にデリバーすることからなるコ力インおよびヘロイン耽溺の治療方法 | |
| US6868286B1 (en) | Device for a transdermal and phonophoretic combination therapy and the use thereof in a method for medical application | |
| AU2015238858A1 (en) | Pharmacokinetics of iontophoretic sumatriptan administration | |
| US20060062735A1 (en) | Combination therapy and means for carrying out said therapy | |
| Streisand et al. | Newer drug delivery systems | |
| CN101002756A (zh) | 盐酸奈福泮的透皮贴片制剂 | |
| KR20050016985A (ko) | 조합 치료법 및 이 치료법을 수행하기 위한 수단 | |
| CN101019844A (zh) | 盐酸曲马多的透皮贴片制剂 | |
| CN101019867A (zh) | 盐酸丁丙诺啡的透皮贴片制剂 |